TAT-11: “Ac-225-NM600 Targeted Alpha Therapy Extends Survival in a Model of Triple Negative Breast Cancer”

Ottawa, ON, Canada (UroToday.com) This study explores the use of Ac225-NM600 for the treatment of triple negative breast cancer in a mouse model. NM600 is an example of analkyl phosphocholinee analogs. Ac225-NM600 was injected in mice with mammary adenocarcinoma 4T1 tumor grafts at doses of either 20 kBq or 40 kBq. Significant tumor reduction was observed at both dose, but only the lower dose improved overall survive. The larger dose was too toxic.


Presented by: Reinier Hernandez, Ph.D., Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, United States

Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada